Guanylyl cyclase activation reverses resistive breathing-induced lung injury and inflammation

American Journal of Respiratory Cell and Molecular Biology

Volumn 52, Issue 6, 2015, Pages 762-771

  Glynos, Constantinos ^a,c   Toumpanakis, Dimitris ^a   Loverdos, Konstantinos ^a   Karavana, Vassiliki ^a   Zhou, Zongmin ^a   Magkou, Christina ^a   Dettoraki, Maria ^a   Perlikos, Fotis ^a   Pavlidou, Athanasia ^a   Kotsikoris, Vasilis ^c   Topouzis, Stavros ^c   Theocharis, Stamatios E ^b   Brouckaert, Peter ^e,f   Giannis, Athanassios ^d   Papapetropoulos, Andreas ^a,c   Vassilakopoulos, Theodoros ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF PATRAS   (Greece)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e GHENT UNIVERSITY   (Belgium)

^f DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

Lung injury; Soluble guanylyl cyclase; Tracheal banding

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; CINACIGUAT; CYCLIC GMP; GUANOSINE PHOSPHATE; GUANYLATE CYCLASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; PHOSPHODIESTERASE V; SOLUBLE GUANYLYL CYCLASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BENZOIC ACID DERIVATIVE;

ACUTE LUNG INJURY; AIRWAY RESISTANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREATHING; BREATHING MECHANICS; CELL INFILTRATION; CONTROLLED STUDY; DISEASE EXACERBATION; DOWN REGULATION; ELASTICITY; ENZYME ACTIVATION; ENZYME DEFICIENCY; ENZYME INHIBITION; GENE EXPRESSION; HISTOPATHOLOGY; HYDROLYSIS; LEUKOCYTE; LUNG COMPLIANCE; LUNG INFILTRATE; LUNG INJURY; LUNG LAVAGE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PNEUMONIA; PRESSURE VOLUME CURVE; PROTEIN CONTENT; PROTEIN EXPRESSION; RESISTIVE BREATHING; SIGNAL TRANSDUCTION; SURFACE AREA; WESTERN BLOTTING; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG SCREENING; ENZYMOLOGY; LUNG DISEASES, OBSTRUCTIVE; METABOLISM;

ANIMALIA; MUS;

AIRWAY RESISTANCE; ANIMALS; BENZOATES; CYCLIC GMP; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; GUANYLATE CYCLASE; LUNG DISEASES, OBSTRUCTIVE; LUNG INJURY; MALE; MICE, INBRED C57BL;

EID: 84930397491     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2014-0092OC     Document Type: Article

References (30)

1. Toumpanakis D, Kastis GA, Zacharatos P, Sigala I, Michailidou T, Kouvela M, Glynos C, Divangahi M, Roussos C, Theocharis SE, et al. Inspiratory resistive breathing induces acute lung injury. Am J Respir Crit Care Med 2010;182:1129-1136.
2. Willms D, Shure D. Pulmonary edema due to upper airway obstruction in adults. Chest 1988;94:1090-1092.
3. Friebe A, Koesling D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res 2003;93:96-105.
4. Glynos C, Dupont LL, Vassilakopoulos T, Papapetropoulos A, Brouckaert P, Giannis A, Joos GF, Bracke KR, Brusselle GG. The role of soluble guanylyl cyclase in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;188:789-799.
5. Papapetropoulos A, Simoes DC, Xanthou G, Roussos C, Gratziou C. Soluble guanylyl cyclase expression is reduced in allergic asthma. Am J Physiol Lung Cell Mol Physiol 2006;290:L179-L184.
6. Glynos C, Kotanidou A, Orfanos SE, Zhou Z, Simoes DC, Magkou C, Roussos C, Papapetropoulos A. Soluble guanylyl cyclase expression is reduced in LPS-injury IL. Am J Physiol Regul Integr Comp Physiol 2007;292:R1448-R1455.
7. Egemnazarov B, Sydykov A, Schermuly RT, Weissmann N, Stasch JP, Sarybaev AS, Seeger W, Grimminger F, Ghofrani HA. Novel soluble guanylyl cyclase stimulator BAY 41-2272 attenuates ischemia-reperfusion-induced lung injury. Am J Physiol Lung Cell Mol Physiol 2009;296:L462-L469.
8. Gerassimou C, Kotanidou A, Zhou Z, Simoes DC, Roussos C, Papapetropoulos A. Regulation of the expression of soluble guanylyl cyclase by reactive oxygen species. Br J Pharmacol 2007;150: 1084-1091.
9. Pyriochou A, Beis D, Koika V, Potytarchou C, Papadimitriou E, Zhou Z, Papapetropoulos A. Soluble guanylyl cyclase activation promotes angiogenesis. J Pharmacol Exp Ther 2006;319:663-671.
10. Vassilakopoulos T, Zakynthinos S, Roussos C. Strenuous resistive breathing induces proinflammatory cytokines and stimulates the hpa axis in humans. Am J Physiol 1999;277:R1013-R1019.
11. Vassilakopoulos T, Katsaounou P, Karatza MH, Kollintza A, Zakynthinos S, Roussos C. Strenuous resistive breathing induces plasma cytokines: role of antioxidants and monocytes. Am J Respir Crit Care Med 2002;166:1572-1578.
12. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006;5:755-768.
13. Murao Y, Loomis W, Wolf P, Hoyt DB, Junger WG. Effect of dose of hypertonic saline on its potential to prevent lung tissue damage in a mouse model of hemorrhagic shock. Shock 2003;20: 29-34.
14. Allen G, Bates JH. Dynamic mechanical consequences of deep inflation in mice depend on type and degree of lung injury. J Appl Physiol 2004;96:293-300.
15. Harris RS. Pressure-volume curves of the respiratory system. Respir Care 2005;50:78-98.
16. Buechler WA, Nakane M, Murad F. Expression of soluble guanylate cyclase activity requires both enzyme subunits. Biochem Biophys Res Commun 1991;174:351-357.
17. Filippov G, Bloch DB, Bloch KD. Nitric oxide decreases stability of mRNAs encoding soluble guanylate cyclase subunits in rat pulmonary artery smooth muscle cells. J Clin Invest 1997;100: 942-948.
18. Papapetropoulos A, Abou-Mohamed G, Marczin N, Murad F, Caldwell RW, Catravas JD. Downregulation of nitrovasodilator-induced cyclic GMP accumulation in cells exposed to endotoxin or interleukin-1 beta. Br J Pharmacol 1996;118:1359-1366.
19. Papapetropoulos A, Go CY, Murad F, Catravas JD. Mechanisms of tolerance to sodium nitroprusside in rat cultured aortic smooth muscle cells. Br J Pharmacol 1996;117:147-155.
20. Takata M, Filippov G, Liu H, Ichinose F, Janssens S, Bloch DB, Bloch KD. Cytokines decrease sGC in pulmonary artery smooth muscle cells via NO-dependent and NO-independent mechanisms. Am J Physiol Lung Cell Mol Physiol 2001;280:L272-L278.
21. Mehta S. The effects of nitric oxide in acute lung injury. Vascul Pharmacol 2005;43:390-403.
22. Buys ES, Sips P, Vermeersch P, Raher MJ, Rogge E, Ichinose F, Dewerchin M, Bloch KD, Janssens S, Brouckaert P. Gender-specific hypertension and responsiveness to nitric oxide in sGCalpha1 knockout mice. Cardiovasc Res 2008;79:179-186.
23. Chester M, Seedorf G, Tourneux P, Gien J, Tseng N, Grover T, Wright J, Stasch JP, Abman SH. Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2011;301:L755-L764.
24. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H S AK, Meurer S, Deile M, Taye A, Knorr A, Lapp H, et al. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 2006;116:2552-2561.
25. Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2011;123:2263-2273.
26. Ahluwalia A, Foster P, Scotland RS, McLean PG, Mathur A, Perretti M, Moncada S, Hobbs AJ. Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci USA 2004; 101:1386-1391.
27. Stephens RS, Rentsendorj O, Servinsky LE, Moldobaeva A, Damico R, Pearse DB. cGMP increases antioxidant function and attenuates oxidant cell death in mouse lung microvascular endothelial cells by a protein kinase G-dependent mechanism. Am J Physiol Lung Cell Mol Physiol 2010;299:L323-L333.
28. Vandendriessche B, Rogge E, Goossens V, Vandenabeele P, Stasch JP, Brouckaert P, Cauwels A. The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems. PLoS One 2013;8: e72155.
29. Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013;369:319-329.
30. Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369:330-340.